RxDoctor Payments DataLook up a doctor →

Anthony Dota, MD

Interventional Cardiology · Las Vegas, NVNPI 1568653384

Payments from drug & device makers

$17,571in general payments, 2019–2025

Across 507 payments — averaging $34.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Abbott$2K
  • Shockwave Medical, Inc$2K
  • Penumbra, Inc.$2K
  • Abiomed$1K
  • Novartis$1K
  • plus $7K from 39 others

What the payments were for

  • Travel & lodging$6214%
  • Food & beverage$16,95096%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,571 in reported general payments places this provider in the 70th percentile of 62 interventional cardiology providers in Nevada.

See all interventional cardiology providers in Nevada

Medicare billing

Part B allowed, 2024
$391,464
Medicare patients
1,192
Services billed
3,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$152,047
XareltoRivaroxaban49$61,869
Repatha SureclickEvolocumab21$27,599
EntrestoSacubitril/Valsartan16$20,380
BrilintaTicagrelor13$12,644
VascepaIcosapent Ethyl14$8,561
Praluent PenAlirocumab11$5,443
ClopidogrelClopidogrel Bisulfate188$1,897
Atorvastatin Calcium199$1,830
Hydralazine Hcl113$1,756
Ranolazine ErRanolazine25$1,502
Metoprolol Succinate98$1,442
Labetalol Hcl31$1,441
Losartan Potassium112$946
Metoprolol Tartrate170$877

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$387$152,047130 claims
Johnson & JohnsonXarelto$210$61,86949 claims
NovartisEntresto$1,268$20,38016 claims
AstraZenecaBrilinta$65$12,64413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 62 interventional cardiology providers in Nevada.

Other interventional cardiology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →